Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director | September 28, 2026 | September 30, 2026 |
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Director | December 28, 2022 | December 30, 2022 |
| OmniAb, Inc.OABI · Entity 5294 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date September 28, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,254 |
Ending reported balance
After 2026-09-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-28 · Exercise / conversion · Acquired 15,940 · Balance 82,816 Row 2 · 2026-09-28 · Tax withholding · Disposed 5,562 · Balance 77,254 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.30 · Expires 2026-10-26 | Direct | 0 |
Reported balance
After 2026-09-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-28 · Exercise / conversion · Disposed 15,940 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2027-10-26 | Direct | 12,500 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 12,500 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.96 · Expires 2028-10-25 | Direct | 7,592 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 7,592 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.41 · Expires 2029-10-24 | Direct | 8,044 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 8,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.92 · Expires 2030-10-29 | Direct | 6,028 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 6,028 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.81 · Expires 2031-10-28 | Direct | 2,532 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 2,532 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.94 · Expires 2032-10-27 | Direct | 3,460 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 3,460 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.51 · Expires 2033-10-26 | Direct | 3,937 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 3,937 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.37 · Expires 2034-10-24 | Direct | 3,511 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 3,511 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.96 · Expires 2035-10-30 | Direct | 3,777 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 3,777 F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
LIGAND PHARMACEUTICALS INC
Report date December 28, 2022 · Filed December 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 417,695 |
Reported balance
After 2022-12-28 transaction · row 1
1 source rowRow 1 · 2022-12-28 · Tax withholding · Disposed 5,289 · Balance 417,695 |
OmniAb, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,962,320 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Exercise / conversion · Acquired 20,000 · Balance 2,962,320 F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Exercise / conversion · Disposed 20,000 · Balance 0 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2026-06-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-17 · Grant · Acquired 20,000 · Balance 20,000 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.03 · Expires 2036-06-17 | Direct | 40,000 |
Reported balance
After 2026-06-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-17 · Grant · Acquired 40,000 · Balance 40,000 F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2017 Filed Jun 23, 2017 20:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 4,666 | $21.00 | $97,986.00 |
DisclosureSEC source: 0000886163-17-000081 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on May 11, 2017, in accordance with Rule 10b5-1. Read SEC document |
| June 09, 2017 Filed Jun 9, 2017 23:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000079 · edgardoc.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,483 Underlying: Common Stock · 12,000 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on May 11, 2017, in accordance with Rule 10b5-1. F3 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 2/23/08. Read SEC document |
| June 09, 2017 Filed Jun 9, 2017 23:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 12,000 | $114.87 | $1,378,440.00 |
DisclosureSEC source: 0000886163-17-000079 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,171 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on May 11, 2017, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.96 to $115.70, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 09, 2017 Filed Jun 9, 2017 23:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 12,000 | $21.00 | $252,000.00 |
DisclosureSEC source: 0000886163-17-000079 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on May 11, 2017, in accordance with Rule 10b5-1. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 21:49 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 4,000 | $109.10 | $436,400.00 |
DisclosureSEC source: 0000886163-17-000044 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,171 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 22, 2016, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.49 to $109.48, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 23:03 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 15,675 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000886163-17-000042 · edgardoc.xml · derivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,675 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/17/11. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 23:03 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,473 | $106.92 | $157,493.16 |
DisclosureSEC source: 0000886163-17-000042 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,171 F2 · shares: Represents previously-owned shares delivered to the Issuer in payment of the exercise price of the stock options. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 23:03 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 15,675 | $10.05 | $157,533.75 |
DisclosureSEC source: 0000886163-17-000042 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 23:03 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 4,000 | $107.06 | $428,240.00 |
DisclosureSEC source: 0000886163-17-000042 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,969 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.13, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 43,646 | $0.00 Strike: $100.38 | $0.00 |
DisclosureSEC source: 0000886163-17-000028 · edgardoc.xml · derivative · entry 6 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,646 Underlying: Common Stock · 43,646 shares Expires 2027-02-24 F5 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Optioned Shares per month thereafter. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 10,224 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000028 · edgardoc.xml · nonDerivative · entry 5 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,969 Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 4,783 | $100.38 | $480,117.54 |
DisclosureSEC source: 0000886163-17-000028 · edgardoc.xml · nonDerivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,745 F4 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 9,168 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000028 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,528 F3 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer?s common stock. The PSUs were originally granted on 02/10/2015 and were eligible to vest based on the Issuer?s achievement of certain performance objectives during the two-year performance period ending December 31, 2016. On February 24, 2017, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer?s achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| February 15, 2017 Filed Feb 28, 2017 23:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,019 | $104.28 | $210,541.32 |
DisclosureSEC source: 0000886163-17-000028 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,360 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2016. Read SEC document |
| February 15, 2017 Filed Feb 28, 2017 23:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,285 | $104.28 | $238,279.80 |
DisclosureSEC source: 0000886163-17-000028 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,379 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/10/2015. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:17 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0000914190-16-000860 · edgar.xml · derivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,985 shares Expires 2026-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:17 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000860 · edgar.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,273 Read SEC document |
| September 22, 2016 Filed Sep 23, 2016 20:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,000 | $117.34 | $352,020.00 |
DisclosureSEC source: 0000886163-16-000231 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,664 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.25 to $117.46, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 08, 2016 Filed Sep 12, 2016 21:27 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,700 | $109.83 | $186,715.93 |
DisclosureSEC source: 0000914190-16-000831 · edgar.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,359 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.35 to $110.2867 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2008 Filed Jun 23, 2017 20:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 4,666 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000081 · edgardoc.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,666 Underlying: Common Stock · 4,666 shares Expires 2018-02-23 F2 · shares: On February 23, 2008, the Reporting Person was granted an option to purchase 4,666 shares of common stock. The option vested in full on February 15, 2009 based on the satisfaction of certain performance goals. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.